Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

by Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al.
The Lancet – Published Online First, November 4, 2017

11 pp. 1.2 MB
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32758-7.pdf

Few therapeutic options are available to treat late-stage human African trypanosomiasis, a neglected tropical disease caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment nifurtimox eflornithine combination therapy needs to be administered intravenously in a hospital setting by trained personnel, which is not optimal, given that patients often live in remote areas with few health resources. The author’s findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients. Fexinidazole could be a key  asset in the elimination of this fatal neglected disease.

(Visited 5 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.